Zacks Research Issues Negative Outlook for Pfizer Earnings

Pfizer Inc. (NYSE:PFE) – Zacks Research dropped their Q1 2025 earnings per share estimates for Pfizer in a note issued to investors on Thursday, January 2nd. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will post earnings per share of $0.61 for the quarter, down from their prior estimate of $0.68. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Zacks Research also issued estimates for Pfizer’s Q2 2025 earnings at $0.60 EPS, Q3 2025 earnings at $0.83 EPS, Q4 2025 earnings at $0.82 EPS, FY2025 earnings at $2.86 EPS, Q1 2026 earnings at $0.63 EPS, Q2 2026 earnings at $0.61 EPS and Q4 2026 earnings at $0.85 EPS.

A number of other research analysts have also recently issued reports on PFE. Evercore ISI raised Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Sanford C. Bernstein started coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Citigroup began coverage on shares of Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target for the company. Wolfe Research assumed coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective on the stock. Finally, Guggenheim reduced their target price on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $32.15.

Pfizer Price Performance

Shares of PFE stock opened at $27.12 on Monday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer has a 12-month low of $24.48 and a 12-month high of $31.54. The firm has a fifty day moving average of $26.27 and a 200-day moving average of $28.07. The firm has a market capitalization of $153.69 billion, a price-to-earnings ratio of 36.65, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter last year, the firm earned ($0.17) EPS. Pfizer’s quarterly revenue was up 31.2% compared to the same quarter last year.

Hedge Funds Weigh In On Pfizer

A number of institutional investors have recently bought and sold shares of PFE. Sachetta LLC increased its holdings in shares of Pfizer by 7.3% during the 2nd quarter. Sachetta LLC now owns 5,010 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 342 shares during the last quarter. Wells Trecaso Financial Group LLC increased its holdings in shares of Pfizer by 2.5% in the third quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company’s stock valued at $416,000 after purchasing an additional 350 shares during the last quarter. Washington Trust Advisors Inc. raised its position in shares of Pfizer by 0.7% in the third quarter. Washington Trust Advisors Inc. now owns 49,216 shares of the biopharmaceutical company’s stock valued at $1,424,000 after purchasing an additional 360 shares during the period. Cullen Investment Group LTD. lifted its stake in shares of Pfizer by 0.9% during the 3rd quarter. Cullen Investment Group LTD. now owns 42,677 shares of the biopharmaceutical company’s stock worth $1,235,000 after buying an additional 377 shares during the last quarter. Finally, MidWestOne Financial Group Inc. boosted its holdings in shares of Pfizer by 1.5% during the 2nd quarter. MidWestOne Financial Group Inc. now owns 26,530 shares of the biopharmaceutical company’s stock worth $742,000 after buying an additional 386 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Activity

In other news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is currently owned by insiders.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.34%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is currently 232.43%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.